Passage BIO, Inc. - 8-K Filing

Remix Therapeutics reports 57% overall response rate for REM-422 in biomarker-positive adenoid cystic carcinoma patients. (Items: 7.01 Regulation FD Disclosure On November 19, 2026, Remix Therapeutics, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PASG

Read the full article at SEC EDGAR

Part of the story Passage BIO, Inc. - 8-K Filing (3 articles)

More Regulatory news